Pure Global
NCT06338072

Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX/1).

Impact of the Menstrual Cycle on the Control of Type 1 Diabetes in Reproductive Aged Women Using an Advanced Closed Loop System.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·ClinicalTrials.govRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes
Study type
Observational
Sponsor & location
Primary sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Location
Madrid, Spain
Timeline & enrollment
Phase
N/A
Start date
Mar 03, 2024
End date
Aug 01, 2025
Enrollment
119 participants
Primary outcome

Time in range

Summary

The aim of this observational study is to assess the effectiveness of automatic insulin
 infusion in responding to changes in insulin sensitivity throughout various phases of the
 menstrual cycle in a cohort of reproductive-aged women with type 1 diabetes, using an
 advanced closed-loop system. By gaining insights into both the limitations and effectiveness
 of this adaptation, we aim to inform the enhancement of control algorithms and learning
 strategies within closed-loop systems. This research is especially vital for addressing the
 distinct challenges that women commonly encounter in maintaining glycemic control.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06338072
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06338072 through Pure Global AI's free database. This phase not specified trial is sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal and is currently Recruitment Completed. The study focuses on Type 1 Diabetes. Target enrollment is 119 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.